IRLAB’s Phase IIb Study with Pirepemat Passes DSMB Safety Review with Unanimous Recommendation to Continue the Ongoing Phase IIb Study
GOTHENBURG, SWEDEN / ACCESSWIRE / July 17, 2023 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, July 17, 2023 - IRLAB Therapeutics...